Drug interactions in childhood cancer

The Lancet Oncology

Volumn 12, Issue 1, 2011, Pages 92-99

  Haidar, Cyrine ^a   Jeha, Sima ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; APREPITANT; AZATHIOPRINE; CARBAMAZEPINE; CISPLATIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IFOSFAMIDE; ITRACONAZOLE; MERCAPTOPURINE; METHOTREXATE; NAVELBINE; OMEPRAZOLE; ONDANSETRON; PHENYTOIN; PREDNISONE; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; VALPROIC ACID; VINBLASTINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALTERNATIVE MEDICINE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG COMPETITION; DRUG EFFICACY; DRUG INTERACTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; FOOD DRUG INTERACTION; GASTRITIS; GLIOMA; GRAPEFRUIT; HERB DRUG INTERACTION; HUMAN; HYPERURICEMIA; LEG DISEASE; LIMB DISEASE; LIVER TOXICITY; LYMPHOMA; MYCOSIS; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; PARALYSIS; PARALYTIC ILEUS; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEIZURE; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME;

ANTACIDS; ANTI-INFECTIVE AGENTS; ANTICONVULSANTS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHILD; COMPLEMENTARY THERAPIES; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HUMANS; NEOPLASMS;

EID: 78650695931     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70105-4     Document Type: Review

References (73)

1. Balis FM, Holcenberg JS, Zimm S, et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 1987, 41:384-387.
2. Furman WL, Navid F, Daw NC, et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 2009, 27:4599-4604.
3. A snapshot of Pediatric Cancer National Cancer Institute, (accessed August, 2009). http://planning.cancer.gov/disease/snapshots.shtml.
4. Blower P, de Wit R, Goodin S, Aapro M Drug-drug interactions in oncology: why are they important and can they be minimized?. Crit Rev Oncol Hematol 2005, 55:117-142.
5. Kearns GL, bdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003, 349:1157-1167.
6. McLeod HL, Krynetski EY, Relling MV, Evans WE Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000, 14:567-572.
7. Evans WE, Relling MV Moving towards individualized medicine with pharmacogenomics. Nature 2004, 429:464-468.
8. Beijnen JH, Schellens JHM Drug interactions in oncology. Lancet Oncol 2004, 5:489-496.
9. Evans WE, Relling MV Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
10. Cavallari LM, Ellingrod VL, Kolesar JM Pharmaco-genomics handbook 2009, Lexi-Comp, Inc. 2nd edn.
11. Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000, 356:285-290.
12. Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol 2005, 27:389-392.
13. Kashuba AD Drug metabolism, transport, and the influence of hepatic disease. Applied pharmacokinetics and pharmacodynamics 2006, 121-164. Lippincott Williams & Wilkins, Philadelphia. 4th edn. M.E. Burton, L.M. Shaw, J.J. Schentag, W.E. Evans (Eds.).
14. Madadi P, Koren G Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics 2008, 9:1267-1284.
15. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998, 101:847-854.
16. Ho RH, Kim RB Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005, 78:260-277.
17. McLeod HL Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998, 45:539-544.
18. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994, 12:1667-1672.
19. Alberts DS, Peng YM, Chen HS, Struck RF Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse. Br J Cancer 1978, 38:316-324.
20. Murry DJ, Cherrick I, Salama V, et al. Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol 2002, 24:130-133.
21. Rodman JH, Murry DJ, Madden T, Santana VM Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994, 12:2390-2397.
22. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999, 66:589-593.
23. Yap KY, Chui WK, Chan A Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008, 30:1385-1407.
24. Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001, 12:217-219.
25. Curran MP, Robinson DM Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009, 69:1853-1878.
26. Jarkowski A Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. Am J Health Syst Pharm 2008, 65:2229-2231.
27. deJonge ME, Huitema AD, Holtkamp MJ, van Dam SM, Beijnen JH, Rodenhuis S Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005, 56:370-378.
28. Loos WJ, de Wit R, Freedman SJ, et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007, 59:407-412.
29. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003, 74:17-24.
30. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006, 24:2932-2947.
31. Kishi S, Yang W, Boureau B, et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004, 103:67-72.
32. Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ, Jones RB Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999, 24:1-4.
33. Spector T Inhibition of urate production by allopurinol. Biochem Pharmacol 1977, 26:355-358.
34. Coffey JJ, White CA, Lesk AB, Rogers WI, Serpick AA Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients. Cancer Res 1972, 32:1283-1289.
35. Zimm S, Collins JM, O'Neill D, Chabner BA, Poplack DG Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983, 34:810-817.
36. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005, 19:34-38.
37. Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J Potential interaction between methotrexate and omeprazole. Ann Pharmacother 2000, 34:1024-1027.
38. Suzuki K, Doki K, Homma M, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009, 67:44-49.
39. Crom WR, Pratt CB, Green AA, et al. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. J Clin Oncol 1984, 2:655-661.
40. Salim A, Tan E, Ilchyshyn A, Berth-Jones J Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006, 154:1169-1174.
41. Izzedine H, Launay-Vacher V, Deray G Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005, 45:804-817.
42. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992, 42:121-125.
43. Williams WM, Chen TS, Huang KC Effect of penicillin on the renal tubular secretion of methotrexate in the monkey. Cancer Res 1984, 44:1913-1917.
44. Basin KS, Escalante A, Beardmore TD Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J Rheumatol 1991, 18:609-610.
45. Callaghan R, Crowley E, Potter S, Kerr ID P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 2008, 48:365-378.
46. Kim RB Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002, 34:47-54.
47. Egorin MJ, Shah DD, Christner SM, et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol 2009, 68:370-374.
48. Eiden C, Palenzuela G, Hillaire-Buys D, et al. Posaconazole-increased vincristine neurotoxicity in a child: a case report. J Pediatr Hematol Oncol 2009, 31:292-295.
49. Kamaluddin M, McNally P, Breatnach F, et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001, 90:1204-1207.
50. Romero AJ, Le PP, Nilsson LG, Wood N Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002, 71:226-234.
51. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995, 58:15-19.
52. Sud K, Singh B, Krishna VS, et al. Unpredictable cyclosporin-fluconazole interaction in renal transplant recipients. Nephrol Dial Transplant 1999, 14:169-703.
53. Pai MP, Allen S Voriconazole inhibition of tacrolimus metabolism. Clin Infect Dis 2003, 36:1089-1091.
54. Fanta S, Jonsson S, Backman JT, Karlsson MO, Hoppu K Developmental pharmacokinetics of ciclosporin-a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol 2007, 64:772-784.
55. Fukudo M, Yano I, Masuda S, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 2006, 80:331-345.
56. Bergstrom P, Johnsson A, Cavallin-Stahl E, Bergenheim T, Henriksson R Effects of cisplatin and amphotericin B on DNA adduct formation and toxicity in malignant glioma and normal tissues in rat. Eur J Cancer 1997, 33:153-159.
57. Titier K, Lagrange F, Pehourcq F, Moore N, Molimard M Pharmacokinetic interaction between high-dose methotrexate and oxacillin. Ther Drug Monit 2002, 24:570-572.
58. Haas A, Anderson L, Lad T The influence of aminoglycosides on the nephrotoxicity of cis-diamminedichloroplatinum in cancer patients. J Infect Dis 1983, 147:363.
59. Govert JA, Patton S, Fine RL Pancytopenia from using trimethoprim and methotrexate. Ann Intern Med 1992, 117:877-878.
60. Ferrazzini G, Klein J, Sulh H, Chung D, Griesbrecht E, Koren G Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr 1990, 117:823-826.
61. Fardel O, Lecureur V, Loyer P, Guillouzo A Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol 1995, 49:1255-1260.
62. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2009, 44:371-374.
63. Cassano WF Serious methotrexate toxicity caused by interaction with ibuprofen. Am J Pediatr Hematol Oncol 1989, 11:481-482.
64. Frenia ML, Long KS Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother 1992, 26:234-237.
65. Weintraub M, Adde MA, Venzon DJ, et al. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 1996, 14:935-940.
66. Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mando OG Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007, 13:6111-6608.
67. Brunner LJ, Pai KS, Munar MY, Lande MB, Olyaei AJ, Mowry JA Effect of grapefruit juice on cyclosporin A pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2000, 4:313-321.
68. Reif S, Nicolson MC, Bisset D, et al. Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol 2002, 58:491-494.
69. de Lemos ML, Hamata L, Jennings S, Leduc T Interaction between mercaptopurine and milk. J Oncol Pharm Pract 2007, 13:237-240.
70. Riccardi R, Balis FM, Ferrara P, Lasorella A, Poplack DG, Mastrangelo R Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1986, 3:319-324.
71. Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002, 72:276-287.
72. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002, 94:1247-1249.
73. Sparreboom A, Cox MC, Acharya MR, Figg WD Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004, 22:2489-2503.